4.7 Article

COVID-19 Vaccine Acceptance among Liver Transplant Recipients

期刊

VACCINES
卷 9, 期 11, 页码 -

出版社

MDPI
DOI: 10.3390/vaccines9111314

关键词

COVID-19 vaccine; COVID-19; vaccination hesitancy; vaccine hesitancy; liver transplantation; liver transplant

向作者/读者索取更多资源

Most LT patients accepted COVID-19 vaccines, with a refusal rate of 6.1%. Identifying reasons influencing vaccination hesitancy is crucial to ensure adequate vaccination of LT patients, and targeted communication strategies should be established for specific vaccination campaigns.
(1) Background: COVID-19 vaccination hesitancy is a threat for fragile patients. We aimed to evaluate COVID-19 vaccination hesitancy and its reasons in a population of liver transplant (LT) recipients. (2) Methods: In February 2021, a questionnaire on COVID-19 vaccines was sent to LT patients followed at our liver transplant outpatient clinic in Milan, Italy. Sociodemographic and clinical characteristics were recorded. Patients were defined as willing, hesitant, or refusing and their reasons were investigated. Associations between baseline characteristics and willingness were evaluated. Since March 2021, when the COVID-19 vaccines became available for LT candidates and recipients in Italy, the entire cohort of LT recipients was contacted by phone and called for vaccination, and the rate of refusals recorded. (3) Results: The web-based survey was sent to 583 patients, of whom 190 responded (response rate of 32.6%). Among the respondents to the specific question about hesitancy (184), 157 (85.3%) were willing to be vaccinated against COVID-19, while 27 (14.7%) were hesitant. Among the hesitant, three were totally refusing, for a refusal rate of 1.6%. Thirteen hesitant patients (48.1%) answered that their COVID-19 vaccination hesitancy was influenced by being a transplant recipient. The fear of adverse effects was the main reason for refusal (81.5%). Of the 711 LT patients followed at our center, 668 got fully vaccinated, while 43 (6.1%) of them refused the scheduled vaccination. (4) Conclusions: Most patients accepted COVID-19 vaccines, although 6.1% refused the vaccine. Since it is crucial to achieve adequate vaccination of LT patients, it is very important to identify the reasons influencing COVID-19 vaccination hesitancy so that appropriate and targeted communication strategies can be established and specific vaccination campaigns further implemented.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Gastroenterology & Hepatology

Bulevirtide for patients with compensated chronic hepatitis delta: A review

Elisabetta Degasperi, Maria P. Anolli, Pietro Lampertico

Summary: Chronic hepatitis delta (CHD) is a severe form of chronic viral hepatitis, affecting millions of people worldwide. The only treatment option for CHD, interferon, has limited efficacy and significant side effects. Bulevirtide (BLV) has shown promising results as a new HBV-HDV entry inhibitor, with high virological response rates and good tolerability. BLV has received conditional approval for the treatment of compensated CHD, providing a new treatment option for patients.

LIVER INTERNATIONAL (2023)

Article Gastroenterology & Hepatology

Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center study

Massimo Iavarone, Giulia Tosetti, Floriana Facchetti, Matilde Topa, Joey Ming Er, Shou Kit Hang, Debora Licari, Andrea Lombardi, Roberta D'Ambrosio, Elisabetta Degasperi, Alessandro Loglio, Chiara Oggioni, Riccardo Perbellini, Riccardo Caccia, Alessandra Bandera, Andrea Gori, Ferruccio Ceriotti, Luigia Scudeller, Antonio Bertoletti, Pietro Lampertico

Summary: This study found that patients with cirrhosis have a suboptimal immune response to COVID-19 vaccines, particularly in those who have not been infected with SARS-CoV-2 before. However, the cellular immune response in patients with cirrhosis remains preserved, and a low rate of breakthrough infections was observed.

DIGESTIVE AND LIVER DISEASE (2023)

Article Gastroenterology & Hepatology

Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection

Harry L. A. Janssen, Jinlin Hou, Tarik Asselah, Henry L. Y. Chan, Fabien Zoulim, Yasuhito Tanaka, Ewa Janczewska, Ronald G. Nahass, Stefan Bourgeois, Maria Buti, Pietro Lampertico, Oliver Lenz, Thierry Verbinnen, Joris Vandenbossche, Willem Talloen, Ronald Kalmeijer, Maria Beumont, Michael Biermer, Umesh Shukla

Summary: The study evaluated the efficacy and safety of JNJ-56136379 in patients with chronic hepatitis B. The results showed that JNJ-56136379+NA significantly reduced HBV DNA and HBV RNA levels, but had limited effects on HBsAg or HBeAg declines in HBeAg-positive patients. Overall, JNJ-56136379 did not demonstrate clear superiority over NA in terms of efficacy.
Article Gastroenterology & Hepatology

Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro

Marzia Rossi, Andrea Vecchi, Camilla Tiezzi, Valeria Barili, Paola Fisicaro, Amalia Penna, Ilaria Montali, Stephane Daffis, Simon P. Fletcher, Anuj Gaggar, Jonathan Medley, Michael Graupe, Latesh Lad, Alessandro Loglio, Roberta Soffredini, Marta Borghi, Teresa Pollicino, Cristina Musolino, Arianna Alfieri, Federica Brillo, Diletta Laccabue, Marco Massari, Chiara Boarini, Gianluca Abbati, Giuseppe Pedrazzi, Gabriele Missale, Pietro Lampertico, Carlo Ferrari, Carolina Boni

Summary: This study characterized the functional impairment of exhausted HBV-specific CD8 T cells in patients with chronic HBV infection. It identified subsets of patients with different capacities to control infection and respond to immune modulation. It also found that functionally more efficient HBV-specific CD8 T cell subsets with lower expression of coinhibitory molecules were present in some chronic viraemic patients. The ability to distinguish patient cohorts with different responses to immune modulation through phenotypic CD8 T cell exhaustion profiling is clinically significant.
Review Gastroenterology & Hepatology

Bulevirtide-based treatment strategies for chronic hepatitis delta: A review

Elisabetta Degasperi, Maria Paola Anolli, Pietro Lampertico

Summary: Chronic hepatitis Delta (CHD) is a rare and severe form of chronic viral hepatitis. The current treatment approach is the off-label use of PegInterferon alpha (PegIFN alpha), but it has suboptimal efficacy and significant side effects. The entry inhibitor Bulevirtde (BLV) has been conditionally approved for the treatment of compensated CHD and has shown promising results in clinical trials and real-life studies.

JOURNAL OF VIRAL HEPATITIS (2023)

Article Gastroenterology & Hepatology

Long-term endoscopic surveillance in HBV compensated cirrhotic patients treated with Tenofovir or Entecavir for 11 years

Elisa Farina, Alessandro Loglio, Giulia Tosetti, Elisabetta Degasperi, Mauro Vigano, Carmine Gentile, Sara Monico, Riccardo Perbellini, Marta Borghi, Floriana Facchetti, Sara Colonia Uceda Renteria, Ferruccio Ceriotti, Federica Cerini, Massimo Primignani, Pietro Lampertico

Summary: In patients with HBV-related compensated cirrhosis receiving long-term TDF/ETV treatment, the risk of developing/progessing EV is negligible, challenging the current endoscopic surveillance recommendations in patients without EV at baseline.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Article Gastroenterology & Hepatology

Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference

Marc G. Ghany, Maria Buti, Pietro Lampertico, Hannah M. Lee

Summary: Representatives from academia, industry, regulatory agencies, and patient advocacy groups convened under the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) in June 2022 to achieve consensus on chronic HBV and HDV treatment endpoints. The conference focused on the primary goal of guiding clinical trials aiming to cure HBV and HDV, and reached agreements on key points such as preferred endpoints for trials, suitable patient candidates, and the role of novel biomarkers and existing therapies.

HEPATOLOGY (2023)

Article Infectious Diseases

Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

Giuseppina Brancaccio, Barbara Coco, Alessandra Nardi, Maria Giovanna Quaranta, Maria Elena Tosti, Luigina Ferrigno, Irene Cacciola, Vincenzo Messina, Luchino Chessa, Filomena Morisco, Michele Milella, Francesco Barbaro, Alessia Ciancio, Francesco Paolo Russo, Nicola Coppola, Pierluigi Blanc, Ernesto Claar, Gabriella Verucchi, Massimo Puoti, Anna Linda Zignego, Liliana Chemello, Salvatore Madonia, Stefano Fagiuoli, Alfredo Marzano, Carlo Ferrari, Pietro Lampertico, Vito Di Marco, Antonio Craxi, Teresa Antonia Santantonio, Giovanni Raimondo, Maurizia R. Brunetto, Giovanni Battista Gaeta, Loreta A. Kondili

Summary: The study examined the characteristics of patients with chronic hepatitis B virus in Italy and found that a significant proportion of patients were non-Italian natives, and there was a decline in HBeAg prevalence and stable anti-HDV prevalence. Cirrhosis was common in both cohorts, with a higher proportion in the PITER cohort, and variables such as age, sex, BMI, and anti-HDV positivity were associated with cirrhosis. The study also observed an increase in adherence to antiviral treatment recommendations over time. In conclusion, chronic hepatitis B virus infection in Italy appears to be under control, but HDV infection remains a health concern.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2023)

Article Gastroenterology & Hepatology

A 3-year course of bulevirtide monotherapy may cure HDV infection in patients with cirrhosis

Maria Paola Anolli, Elisabetta Degasperi, Lena Allweiss, Angelo Sangiovanni, Marco Maggioni, Caroline Scholtes, Valerie Oberhardt, Christoph Neumann-Haefelin, Maura Dandri, Fabien Zoulim, Pietro Lampertico

Summary: Bulevirtide has received conditional approval from the EMA for treating chronic hepatitis delta, but the optimal duration of therapy remains unknown. In this study, a patient with compensated cirrhosis and esophageal varices achieved hepatitis delta cure after 3 years of bulevirtide monotherapy. Virological and biochemical responses were maintained during the 72-week off-therapy follow-up, and significant improvements were observed in liver biopsy results.

JOURNAL OF HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct-acting antivirals

Serena Pelusi, Cristiana Bianco, Massimo Colombo, Giuliana Cologni, Paolo del Poggio, Nicola Pugliese, Daniele Prati, Marie Graciella Pigozzi, Roberta D'Ambrosio, Pietro Lampertico, Stefano Fagiuoli, Luca Valenti

Summary: This study aimed to examine the impact of metabolic dysfunction (MD) on patients cured of chronic hepatis C (CHC). The results showed that MD had a significant effect on liver stiffness in patients with advanced fibrosis and was associated with increased risk of hepatocellular carcinoma (HCC). Further classification based on diagnostic criteria improved risk stratification. Therefore, MD is an effective way to identify individuals at risk of developing HCC in CHC patients.

LIVER INTERNATIONAL (2023)

Review Microbiology

The Impact of Antiviral Treatment of Hepatitis B Virus after Kidney Transplant and the Latest Insights

Fabrizio Fabrizi, Maria Francesca Donato, Federica Tripodi, Anna Regalia, Pietro Lampertico, Giuseppe Castellano

Summary: The aim of this review is to assess the role of antiviral therapy for HBV in improving survival after a kidney transplant. The results suggest a negative correlation between HBV-positive status and survival after a kidney transplant. Antiviral therapy has been shown to improve patient and graft survival in HBV-positive individuals.

PATHOGENS (2023)

Editorial Material Gastroenterology & Hepatology

Hepatitis Delta: Ready for primetime?

Benjamin Maasoumy, Pietro Lampertico

LIVER INTERNATIONAL (2023)

Article Immunology

Attitudes towards Vaccinations in a National Italian Cohort of Patients with Inflammatory Bowel Disease

Andrea Costantino, Marco Michelon, Daniele Noviello, Fabio Salvatore Macaluso, Salvo Leone, Nicole Bonaccorso, Claudio Costantino, Maurizio Vecchi, Flavio Caprioli, AMICI Sci Board

Summary: The vaccination rate against some vaccine-preventable diseases is low among Italian patients with inflammatory bowel disease (IBD), despite a generally positive attitude towards vaccinations.

VACCINES (2023)

Review Gastroenterology & Hepatology

Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022

Pietro Lampertico, Elisabetta Degasperi, Lisa Sandmann, Heiner Wedemeyer

Summary: Chronic infection with hepatitis delta virus (HDV) affects millions of people worldwide, leading to severe liver disease and complications. While progress has been made in understanding the virus, there is still much to learn about its natural history and the immune system's role. Diagnosis and treatment of HDV remain challenging, but recent advancements in antiviral therapy, such as bulevirtide, offer hope for improved outcomes. The first international Delta Cure meeting provided a platform for sharing the latest research and discussing potential strategies for HDV treatment.

JHEP REPORTS (2023)

Article Nutrition & Dietetics

Evaluation of a Single Determination of Gluten Immunogenic Peptides in Urine from Unaware Celiac Patients to Monitor Gluten-Free Diet Adherence

Vincenza Lombardo, Alice Scricciolo, Andrea Costantino, Luca Elli, Giorgia Legnani, Angel Cebolla, Luisa Doneda, Federica Mascaretti, Maurizio Vecchi, Leda Roncoroni

Summary: The aim of this study was to evaluate the clinical efficacy of urinary gluten immunogenic peptides (uGIP) in the follow-up of celiac disease (CD). The results showed that uGIP test can accurately assess the adherence to gluten-free diet and correlated significantly with duodenal biopsy results.

NUTRIENTS (2023)

暂无数据